Potential mechanisms of disease progression and management of advanced-phase chronic myeloid leukemia

Elias J. Jabbour, Timothy P. Hughes, Jorge E. Cortés, Hagop M. Kantarjian, Andreas Hochhaus

Research output: Contribution to journalReview article

Abstract

Despite vast improvements in the treatment of Philadelphia chromosome-positive chronic myeloid leukemia (CML) in chronic phase (CP), advanced stages of CML, accelerated phase or blast crisis, remain notoriously difficult to treat. Treatments that are highly effective against CML-CP produce disappointing results against advanced disease. Therefore, a primary goal of therapy should be to maintain patients in CP for as long as possible, by (1) striving for deep, early molecular response to treatment; (2) using tyrosine kinase inhibitors that lower risk of disease progression; and (3) more closely observing patients who demonstrate cytogenetic risk factors at diagnosis or during treatment.

Original languageEnglish (US)
Pages (from-to)1451-1462
Number of pages12
JournalLeukemia and Lymphoma
Volume55
Issue number7
DOIs
StatePublished - Jul 2014
Externally publishedYes

Fingerprint

Leukemia, Myeloid, Chronic Phase
Disease Management
Disease Progression
Leukemia, Myeloid, Accelerated Phase
TYK2 Kinase
Blast Crisis
Therapeutics
Philadelphia Chromosome
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Cytogenetics

Keywords

  • Drug resistance
  • Myeloid leukemias and dysplasias
  • Tyrosine kinase inhibitor

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Potential mechanisms of disease progression and management of advanced-phase chronic myeloid leukemia. / Jabbour, Elias J.; Hughes, Timothy P.; Cortés, Jorge E.; Kantarjian, Hagop M.; Hochhaus, Andreas.

In: Leukemia and Lymphoma, Vol. 55, No. 7, 07.2014, p. 1451-1462.

Research output: Contribution to journalReview article

Jabbour, Elias J. ; Hughes, Timothy P. ; Cortés, Jorge E. ; Kantarjian, Hagop M. ; Hochhaus, Andreas. / Potential mechanisms of disease progression and management of advanced-phase chronic myeloid leukemia. In: Leukemia and Lymphoma. 2014 ; Vol. 55, No. 7. pp. 1451-1462.
@article{605fc502207f4d13946ac552e664d831,
title = "Potential mechanisms of disease progression and management of advanced-phase chronic myeloid leukemia",
abstract = "Despite vast improvements in the treatment of Philadelphia chromosome-positive chronic myeloid leukemia (CML) in chronic phase (CP), advanced stages of CML, accelerated phase or blast crisis, remain notoriously difficult to treat. Treatments that are highly effective against CML-CP produce disappointing results against advanced disease. Therefore, a primary goal of therapy should be to maintain patients in CP for as long as possible, by (1) striving for deep, early molecular response to treatment; (2) using tyrosine kinase inhibitors that lower risk of disease progression; and (3) more closely observing patients who demonstrate cytogenetic risk factors at diagnosis or during treatment.",
keywords = "Drug resistance, Myeloid leukemias and dysplasias, Tyrosine kinase inhibitor",
author = "Jabbour, {Elias J.} and Hughes, {Timothy P.} and Cort{\'e}s, {Jorge E.} and Kantarjian, {Hagop M.} and Andreas Hochhaus",
year = "2014",
month = "7",
doi = "10.3109/10428194.2013.845883",
language = "English (US)",
volume = "55",
pages = "1451--1462",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Informa Healthcare",
number = "7",

}

TY - JOUR

T1 - Potential mechanisms of disease progression and management of advanced-phase chronic myeloid leukemia

AU - Jabbour, Elias J.

AU - Hughes, Timothy P.

AU - Cortés, Jorge E.

AU - Kantarjian, Hagop M.

AU - Hochhaus, Andreas

PY - 2014/7

Y1 - 2014/7

N2 - Despite vast improvements in the treatment of Philadelphia chromosome-positive chronic myeloid leukemia (CML) in chronic phase (CP), advanced stages of CML, accelerated phase or blast crisis, remain notoriously difficult to treat. Treatments that are highly effective against CML-CP produce disappointing results against advanced disease. Therefore, a primary goal of therapy should be to maintain patients in CP for as long as possible, by (1) striving for deep, early molecular response to treatment; (2) using tyrosine kinase inhibitors that lower risk of disease progression; and (3) more closely observing patients who demonstrate cytogenetic risk factors at diagnosis or during treatment.

AB - Despite vast improvements in the treatment of Philadelphia chromosome-positive chronic myeloid leukemia (CML) in chronic phase (CP), advanced stages of CML, accelerated phase or blast crisis, remain notoriously difficult to treat. Treatments that are highly effective against CML-CP produce disappointing results against advanced disease. Therefore, a primary goal of therapy should be to maintain patients in CP for as long as possible, by (1) striving for deep, early molecular response to treatment; (2) using tyrosine kinase inhibitors that lower risk of disease progression; and (3) more closely observing patients who demonstrate cytogenetic risk factors at diagnosis or during treatment.

KW - Drug resistance

KW - Myeloid leukemias and dysplasias

KW - Tyrosine kinase inhibitor

UR - http://www.scopus.com/inward/record.url?scp=84903461580&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84903461580&partnerID=8YFLogxK

U2 - 10.3109/10428194.2013.845883

DO - 10.3109/10428194.2013.845883

M3 - Review article

C2 - 24050507

AN - SCOPUS:84903461580

VL - 55

SP - 1451

EP - 1462

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 7

ER -